Fisher investing according to Fisher Investing’s latest

According to Fisher Investing’s latest equity outlook, U.S. financials are positioned for potential upside in August as Treasury yields stabilize near 4.25%. Bank earnings indicate improved net interest margins, signaling a possible sector rotation in portfolios. The previous big move we wrote about was 1 day ago when the stock gained 4.8% on the news that reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry. The Trump administration is advancing its “Most Favored Nation” initiative, which aims to lower prescription drug costs for Americans. This policy would tie the prices of medications in the U.S. to the lowest costs paid by other wealthy nations. As part of this push, Pfizer has reportedly entered into an agreement to voluntarily sell its medications through Medicaid at these reduced prices. The move comes as the administration intensifies pressure on drugmakers to make prices more affordable. While pricing controls can often be a headwind, the market's positive reaction suggests that investors may see this voluntary agreement as a way to resolve regulatory uncertainty, providing a clearer path forward for the industry. Institutional Investing Insights Macro Minutes ESG Insights Macro Insights Fisher Investing’s bond-equity correlation study finds lower Treasury volatility helping boost equity valuations. Capital rotation strategies lean toward sectors sensitive to borrowing cost shifts, notably homebuilders and REITs.